Introductory paragraph 19
The application of gene editing technology is currently limited by the lack of safe and efficient 20 methods to deliver RNA-guided endonucleases to target cells. We engineered lentivirus-based 21 nanoparticles to copackage the U6-sgRNA template and the CRISPR-associated protein 9 (Cas9) fused 22 with a virion-targeted protein Vpr (Vpr.Prot.Cas9), for simultaneous delivery to cells. In addition to 23 Vpr, equal spatiotemporal control of the vpr.prot.cas9 and gag/pol gene expression of was required 24 for efficient packaging of the fusion protein into virus particles. Transduction of the unconcentrated, 25
Vpr.Prot.Cas9-containing vectors resulted in >98% disruption of the EGFP gene in reporter HEK293-26 EGFP cells with minimal cytotoxicity. Furthermore, we detected indels in the targeted endogenous loci 27 at frequencies of up to 100% in cell lines derived from lymphocytes and monocytes and up to 15% in 28 primary CD4+ T cells by high-throughput sequencing. This approach may provide a platform for the 29 efficient, safe and selective delivery of genome editing enzymes to cells and it may be suitable for 30 simultaneous gene disruption and transgene delivery. 31 32
Text body 33
The scope and scalability of gene editing systems is currently limited by problems with the delivery of 34 the CRISPR/Cas RNA-guided endonuclease (RGEN) components to recipient cells. Lipofection, 35 electroporation, nucleofection and virus-based techniques are widely used to deliver Cas9/sgRNA 36 expression cassettes. Unfortunately, the methods for delivering DNA have limited cell-type specificity 37 and are associated with side effects, such as integration into undesired chromosomal locations, 38 immunogenicity, size-constrained packaging of expression cassettes (payload limit for AAV ≤4.7 kb) and 39 increased off-targeting resulting from sustained expression. Increasing attention is thus being paid to 40 the direct delivery of preassembled Cas9 protein/sgRNA complexes (RNPs) to cells 1,2 , in which the rapid 41 turnover of RNPs limits the exposure of the genome to nucleases, thereby mitigating off-target effects. 42 Furthermore, the transient occurrence of RNPs in cells is expected to elicit minimal innate and adaptive 43 immune responses, especially when a synthetic sgRNA lacking 5' triphosphates and a Cas9 orthologue 44 derived from a species other than Streptococcus pyogenes are used 3, 4 . Despite the advantages of RNP 45 delivery, the use of this approach is restricted to cell types that do not suffer from reduced cell viability 46 or phenotypic changes following chemical transfection or electroporation. Furthermore, the technology 47 requires laborious optimization of the transfection protocol for every cell type and lacks tissue and cell 48 specificity. Thus, there is an urgent need for a more versatile, safe, cell-selective and "easy-to-use" 49 delivery system. 50
As a result of their efficiency, low toxicity, simplicity of production, mild immunogenicity, relative safety 51 and ease of use and because of the possibility of customizing cell tropism, lentiviral vectors (LVs) are 52 widely used in basic research and are being tested in numerous clinical trials for use in gene therapy 53 (http://www.abedia.com/wiley/index.html) 5,6 . Furthermore, LVs have recently been approved by the 54 FDA for a genetic engineering of T lymphocytes for cancer immunotherapy 7 . In addition to nucleic acids, 55
LVs can also deliver foreign proteins of interest (POIs) to mammalian cells (reviewed in 8 ), and proof-of-56 concept studies have shown that LVs can serve as platforms for the administration of "protein-based" 57 designer nucleases to ablate host genes 9,10 . However, the system suffers from modest effectiveness and 58
is not yet able to deliver the programmable nuclease and the sgRNA simultaneously. We now report an 59 engineered LV that delivers the Cas9 protein and a template for sgRNA in "all-in-one transducing 60 nanoparticles" and efficiently edits the targeted loci in the genome. 61
We postulated that that the large size (~160 kDa) and the net positive charge of Cas9 may cause 62 structural disturbances and lead to reduced transducibility in such a case that the endonuclease is 63 directly linked to the structural components of HIV-1 virions (embedded in the Gag polyprotein). To 64 circumvent this problem, we translationally fused Cas9 containing an N-terminal protease cleavage site 65 (Prot) to the C-terminus of an accessory protein of HIV-1, Vpr. Vpr interacts with the p6 domain of the 66 Gag precursor, thereby mediating the encapsidation of its fusion partners into virions 11 . Previous work 67 with programmable nucleases such as meganucleases, which were packaged into lentiviral particles with 68 the help of Vpr, showed only a moderate efficiency in genome editing, because little nuclease was 69 packaged into virions 9 . Earlier reports showed that retroviral mRNA nuclear export elements regulate 70 protein function and virion assembly 12-15 . Thus, we anticipated that it should be possible to increase the 71 packaging of foreign proteins fused to Vpr, including Vpr.Prot.Cas9, by directing the transport dynamics 72 and/or spatial distribution of the vpr.prot.cas9 transcripts in the same manner as that of the gag mRNA. Figure 1a ). In the presence of Rev, the RRE facilitates mRNA export via the CRM1 pathway, whereas the 81 CTE drives mRNA nuclear exit via the NXF1 pathway 17-20 . The constructs were co-transfected into 82
HEK293T cells together with four complementary plasmids: i) pHCMV-G, which produces the VSV.G 83 envelope protein for pseudotyping virus particles; ii) psPAX2, a second-generation packaging construct, 84 which provides the virion proteins; iii) pRSV-Rev, encoding Rev; and iv) the pLenti(sgRNA) transfer vector 85 containing a U6 promoter driving the expression of an sgRNA specific to the targeted site ( Fig. 1a) . The 86 amounts of Vpr.Prot.Cas9 produced in transfected cells and packaged into produced virions were 87 determined by immunoblotting. The levels of the fusion protein in the cell lysates of cells transfected 88 with the two constructs were the same but the amount of Vpr.Prot.Cas9 packaged into virions was 89 markedly increased when the transcript contained the RRE ( Supplementary Fig. 1c ). The results support 90 the view that the control of spatial localization and/or temporal distribution of transcripts encoding 91 heterologous proteins may be used to facilitate packaging of the protein to virions ( Supplementary Fig.  92 1b). 93
Next, we used an EGFP disruption assay to determine whether the "two-component" lentiviral vector 94 for the combined transduction of the Cas9 protein and U6-sgRNA expression cassette (henceforth 95 referred to as VECTR-Cas), produced from the transfected cells, can deliver the Cas9 protein to the 96 nucleus of mammalian cells, form a complex with nascent sgRNA and induce mutagenesis. We targeted 97 a specific site in a single copy of the EGFP reporter gene incorporated into chromosome 17 of the 98 genome of HEK293 cells (HEK293-EGFP; Supplementary Fig. 2 ). Transduction of the unconcentrated 99 VECTR-Cas(sgGFP) resulted in a robust loss of EGFP in ~90% of the EGFP-expressing cells ( Fig. 1b ; 100 Supplementary Fig. 3a ). 101
Titration of the pVpr.Prot.Cas9 plasmid used to prepare VECTR-Cas(sgGFP) revealed that the greatest 102 extent of reporter EGFP gene disruption (~98%) was achieved with 0.9 µg of the construct in a total 103 amount of 4 µg of transfected DNA ( Supplementary Fig. 4 ). 104
The level of disruption was almost as high as that obtained with the potent cas9 gene-delivering 105 lentiviral vector pLentiCRISPRv2(sgGFP) 21 . The level of EGFP expression was unchanged after 106 transduction of a control lentivector lacking the Vpr.Prot.Cas9 protein or containing an sgRNA that 107 targeted an EMX1 locus ( Fig. 1b; Supplementary Fig. 3b ). No significant EGFP disruption was observed 108 when the vector particles were prepared in the absence of the VSV.G envelope protein or when an 109 inhibitor of reverse transcription, azidothymidine (AZT), was added to transduced cells ( Fig. 1b ; 110 Supplementary Fig. 3b ). 111
To confirm that the disruption of EGFP arose from genome modification and not from Cas9 binding or 112 cellular toxicity, we measured the frequency of insertions/deletions (indels) at the target EGFP locus by 113 means of a T7 endonuclease (T7E1) assay and Inference of CRISPR Edits (ICE) analysis 114 (ice.synthego.com). Both assays revealed the presence of VECTR-Cas-induced double-strand breaks 115 (DSBs) corrected by error-prone nonhomologous end joining (NHEJ). The frequencies of gene disruption 116 differed (38% for T7E1 vs. 97% for ICE) ( Fig. 1c and d ; Supplementary Fig. 5 ), perhaps due to a high 117 frequency of +1 nt insertions (37% of indels) that increased the likelihood of reannealing the mutant 118 DNA strands, leading to insensitivity of the resulting homoduplexes to T7E1 ( Fig. 1c and d ; 119 22 . In contrast to transfection, transduction did not cause any appreciable toxicity 120 in HEK293-EGFP cells, as validated by an XTT assay that showed only a minimal loss of cell viability after 121 transduction ( Supplementary Fig. 6 ). 122
The use of an integration-deficient vector would prevent the possibility of integrating lentiviral DNA, 123 thereby improving the safety of two-component nanoparticles. Efficient knockouts mediated by 124 programmable nucleases require only a short burst of activity, so we reasoned that the expression of 125 sgRNAs from unintegrated viral DNA might be sufficient for gene ablation. We therefore tested the 126 ability of vector particles containing a catalytically inactive integrase protein (D64V, VECTRv2-127 Cas(sgGFP)) 23 to disrupt EGFP. There was no detectable difference in gene ablation activity compared 128 with that of the integration-proficient VECTR-Cas(sgGFP), indicating that the integration-deficient vector 129 is a viable modification of the system ( Fig. 1e; Supplementary Fig. 7) . 130
Transducing HEK293-EGFP cells with decreasing amounts of LVs revealed a positive correlation between 131 the dose of lentiviral vector and the disruption of EGFP. The loss of knockout activity was more 132 pronounced for the two-component VECTRv2-Cas(sgGFP) nanoparticles than for the gene-delivering 133 pLentiCRISPRv2(sgGFP), consistent with the idea that direct protein delivery is more vulnerable to a 134 reduction of the effective nuclease protein concentration than is the administration of a nuclease gene 135 expression cassette ( Supplementary Fig. 8 ). 136
We compared the kinetics of EGFP disruption between VECTRv2-Cas(sgGFP) and pLentiCRISPRv2(sgGFP) 137 by following the expression of EGFP over an 80 h period after transduction. There was no difference in 138 the time course of gene disruption. Both RGEN delivery methods required a lag period of over 24 h to 139 disrupt EGFP, which was followed by a steady increase in disruption, plateauing at 56 h post 140 transduction ( Fig. 1f; Supplementary Fig. 9a ). The loss of fluorescence remained stable over a period of 141 35 days after treatment ( Supplementary Fig. 9b ). In combination with the findings obtained with AZT, 142 which indicated that reverse transcription is required for site-specific mutagenesis ( Fig. 1b) , these 143 results support a model whereby a complex between Cas9 and sgRNA is formed in the nucleus of the 144 recipient cells rather than during the assembly of viral particles (Fig. 2) . 145
To ensure that disruption of EGFP is not a peculiarity of the sgRNA used (sgGFP site No. 1), we tested the 146 activity of a set of EGFP-targeting sgRNAs (sgGFP site Nos. 2─8). One of these sgRNAs (targeting site No. 147
2) induced indels with a frequency comparable to that mediated by the original sgRNA. The remaining 148 six sgRNAs yielded mutation rates that ranged from 12% to 85% (Fig. 1g) . The gene delivery vectors 149 consistently exhibited more robust editing activity than the vectors that directly transferred the Cas9 150 protein, although the magnitude of the difference was not the same for all sites. The effect was 151 particularly salient for the sgRNA that targeted site No. 8, which was the least edited site ( Fig. 1g ; 152 Supplementary Fig. 10 ). It appears that some of the targeted loci are more sensitive to changes in 153 Cas9/sgRNA concentrations in the cell and thus that the design of the sgRNAs is particularly important 154 for systems that directly deliver RGENs to cells. 155
We next investigated whether the VECTRv2-Cas system is more sensitive than the lentivirus-mediated 156 administration of nucleic acids to Watson-Crick mismatches at the sgRNA-DNA interface. We 157 determined the EGFP disruption activity of both lentivirus-based delivery systems bearing variants of the 158 original sgRNA (sgGFP site No. 1) with adjacent double mismatches at positions 1-19 (numbered in the 3' 159 to 5' direction; Fig. 1h ). Regardless of the route of RGEN administration, the EGFP disruption activity was 160 robust and equivalent to that mediated by the matched sgRNA when the sgRNA contained mismatches 161 at positions 17&18 and 18&19. The sgRNA containing mismatches at position 15&16 yielded less potent 162 editing than the matched sgRNA, and the loss of activity was more dramatic when the sgRNA was 163 transduced into cells together with the Cas9 protein. Of the remaining seven sgRNAs, only 164 sgGFP(11&12) showed appreciable activity and only when delivered via the pLentiCRISPRv2 encoding 165 the nuclease ( Fig. 1i; Supplementary Fig. 11 ). These results are consistent with reports that mismatches 166 at the 5' end of sgRNAs are better tolerated than those at the 3' end and establish that VECTR-Cas-167 mediated editing is more specific than mutagenesis induced by the transduction of the cas9 gene into 168 cells 24, 25 . 169
To test whether virions delivering Cas9 protein:template sgRNA can induce the cleavage of endogenous 170 genes in human cells, we transduced HEK293-EGFP cells with VECTRv2 targeted to the EMX1, FANCF, 171
HEKsite1 and HEKsite3 loci in the human genome. The T7E1 assay revealed that indels formed at all four 172 genomic loci with efficiencies similar to those achieved with cas9 gene-delivering virions (13%─55%) 173 ( Fig. 3a; Supplementary Fig. 12 and 13 ). VECTRv2-Cas can also induce site-specific DSBs in more 174 technically challenging cell types, including the Jurkat, SupT1, IM9, and THP-1 cell lines, as well as 175 primary CD4+ T cells. Indels formed at frequencies ranging from 6% to 70% in all cell types tested ( Fig.  176 3b and c; Supplementary Fig. 14 and 15 ). IM9, THP-1, and CD4+ T cells were less edited, but the two T 177 cell-derived lines, Jurkat and SupT1, were as sensitive to the induction of mutations as HEK293-EGFP 178 cells. We used amplicons generated with genomic DNA from SupT1 and CD4+ T cells for high-throughput 179 sequencing to verify and quantify on-target mutations at the FANCF, HEKs1, and HEKs3 loci. For CD4+ 180 cells, we found indels at frequencies of ~3%, 15%, and 13%, respectively, while transduction of SupT1 yielded cleavage efficiencies of 75%, 100% and 100%, respectively ( Fig. 3d and e ) ( Supplementary Fig.  182 16-18). 183 184 Here, we describe a novel system for the codelivery of the Cas9 protein and a template for sgRNA within 185 lentivirus-based "nanoparticles". The idea is built upon findings that lentiviruses can simultaneously 186 deliver foreign proteins and an episomal viral DNA generated by reverse transcription from the vector 187 RNA genome 9,10 . We have extended this approach to show that episomal DNA can serve as a template 188 for the transcription of sgRNA, which forms a complex with the co-delivered Cas9 protein and targets 189 the nuclease to a specific site in the genome. This strategy leads to robust editing activity that is 190 comparable or even superior to that reported for the direct delivery of Cas9 protein/sgRNA complexes 191 to cells 1,2 . In contrast to chemical transfection or electroporation, virus-mediated delivery is receptor 192 mediated, so the use of pseudotypes bearing natural or engineered envelope proteins would allow 193 selective transfer to essentially any target cell population 6 . This approach may even extend the 194 repertoire of cell types that can be edited to clinically relevant nondividing cells (e.g. neurons, 195 hepatocytes, quiescent lymphocytes and hematopoietic stem cells) that are permissive for the 196 lentivector-mediated transduction of cargos to the nucleus 5 . Additionally, because the removal of cas9 197 transgene from the lentiviral transfer vector makes a space for additional function-conferring elements, 198
we imagine that the approach can be developed to a multiple-component system for simultaneous nanoparticles. First, we fused Cas9 to Vpr rather than to the Gag polyprotein, as we anticipated that the 204 incorporation of the bulky nuclease into Gag would destabilize the virions and lower the efficiency of 205 transduction. Second, we incorporated the RRE into the transcripts encoding Gag and pVpr.Prot.Cas9 206 proteins, providing simultaneous control of transport and spatial distribution to both mRNAs and 207 resulting in the accumulation of Vpr.Prot.Cas9 in viral particles. 12,13 . This probably results from the 208 colocalization of nascent Gag and Vpr.Prot.Cas9 proteins after translation, facilitating the interaction 209 between p6 (in Gag) and Vpr (in Vpr.Prot.Cas9) and stimulating the incorporation of the fusion protein 210 into virions ( Supplementary Fig. 1b) . Alternatively, analogous post-transcriptional regulation of gene 211 expression might have allowed the interaction with a cellular factor responsible for the trafficking of 212 transcripts and/or proteins to the virus assembly site. Third, the Cas9 protein remains embedded in a 213 lentiviral core after receptor-mediated cell entry (where it is protected from degradation) and exploits 214 viral intracellular trafficking routes to travel to the nucleus. Finally, the coordinated intranuclear delivery 215 of Cas9 and viral DNA within a preintegration complex particle probably places the nuclease in close 216 proximity to nascent sgRNA molecules synthesized from viral DNA, facilitating the formation of 217 Cas9/sgRNA RNP complexes (Fig. 2) . 218
In summary, we describe novel multicomponent lentiviral nanoparticles that ferry the Cas9 219 protein:sgRNA template to the nuclei of transduced cells for the transient exposure of the genome to 220 the nuclease that results in the specific disruption of targeted genes. where the U6 promoter drives the expression of sgRNA (5). The nascent sgRNA associates with Cas9 (6) 340 and directs the nuclease to the target site in the genomic DNA (gDNA) for cleavage (7). 341 Please note that the HEKs3 site could not be analyzed by the T7E1 assay due to a single-nucleotide 349 polymorphism (SNP) near the cut site ( Supplementary Fig. 17 
